ClinicalTrials.gg
CompletedNCT06377345Updated Nov 18, 2026

Remote Patient Monitoring Solution for Chronic Respiratory Disease Management

An interventional study of AeviceMD device and Standard care in Asthma, Asthma Attack and Asthma in Children, sponsored by SingHealth Polyclinics. Completed at 1 site in Singapore. Open to participants aged 7 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by SingHealth Polyclinics · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
7 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Asthma with a site in Singapore — 3 open to participants now, 3 under way, 1 of them phase 3. Asthma · Singapore.

Enrollment
12th of 19
173 · median 253
Started
2024
with 1 other
No phase
5 of 25
1 open now
Registered
22nd of 25
by date
Lead sponsor
2 of 25
SingHealth Polyclinics

Among the 25 studies in Asthma with a site in Singapore, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 with no phase, and was the 22nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 25 studies in Asthma with a site in Singapore are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 7 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Asthma with a site in Singapore, or all of them as a file.
02

Study summary

Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation.

Methodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited.

Importance of study: This study will evaluate if the AeviceMD can help improve disease management and reduce recurrence of asthma exacerbation.

Potential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device.

Read the detailed description

The aim of the study is to evaluate the clinical outcomes, self-efficacy, quality of life, utility, and cost-effectiveness of the Aevice device for asthma self-management post exacerbation.

The objectives are to evaluate:

  1. The impact of Aevice on asthma symptom control (using Global Initiative for Asthma (GINA) score)
  2. The impact of Aevice on asthma exacerbation (measure by number of rescue therapy, dose of oral Prednisolone used, referral to emergency department, and hospitalization)
  3. The impact of Aevice on quality of life (using Euro Quality of Life - 5 Dimensions (E!Q5D) and mini-asthma quality of life questionnaire)
  4. The patients' self-efficacy using Aevice (self-developed questionnaire)
  5. The usability (system usability scale) and utility of Aevice (time of use and frequency of use)
  6. The take-up rate and demographics of participants who accept versus decline the use of Aevice
  7. Amount patients are willing to pay for the use of Aevice
  8. Clinician perception and acceptability of using technology for telemonitoring and Aevice device
  9. Evaluate the cost effectiveness of using Aevice

The ratio of adults to pediatrics exacerbation based on our statistics is 10:3 currently. To eliminate bias in age during randomization, stratified sampling is adopted, with a proposed mix of 126 adults and 54 pediatrics (63 adults and 27 pediatrics in each group).

Patients in each of the strata will be randomized in a 1:1 ratio to either intervention or control group according to a computer generated block randomization list. Random permuted blocks are used to ensure balance over time. The block size is determined by the study statistician and will kept confidential from the study team until final database lock. Each Patient will be assigned an individual randomization number upon randomization. This randomization number assigned will identify the patient and will be used for all documentation for this patient in this study. After the patient is screened eligibility and consented to the study, the site coordinator will call the centralized team for the randomization number and assignment. Blinding is not possible in the study team and patient as the intervention group will be receiving the new device.

Control group

The control group will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.

Intervention

The intervention group will receive the Aevice device on top of standard care provided by the Polyclinic. They will use the Aevice device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The Aevice device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician the their lung data from the Aevice application on their phone, for the clinician

The research coordinator will provide the participants with the Aevice device, and download the application on the participants' phone. The participant will be able to observe their trend on the application's dashboard They will be informed to share their lung parameters with their nurse during the follow-up call, and show the doctor data on their lung sounds during the follow-up visit. Participants will return the device at the end of the study period.

The participants will be instructed to contact the research coordinator if they face difficulties using the device. This will include problems with the Aevice device and phone application, or participants' do not know how to use the application.

Recruitment

Rescue therapy is administered by the nurses. The nurses in the Polyclinics will help identify patients in the treatment room who meet the inclusion criteria, and invite them to participate in the study. If the patient is agreeable, the nurse will refer the potential participant to the research coordinator. The doctors who are attending to patients with asthma exacerbation can also refer the patient to the research coordinator. The research coordinator will provide the participant information sheet (PIS), explain the details of the study, and go through the consent process with the participant. If the potential participant agrees to participate in the study, written informed consent will be obtained. After obtaining the informed consent, the research coordinator will collect the baseline data from the participant, allocate them to the group, and provide participants in the intervention group with the device.

The clinicians will be invited by email to participate in the survey and qualitative interview study, with a participant information sheet to understand the study rationale. If they agree to participate, the survey will be sent to them. They can participate in the survey only, and not the qualitative interview.

This study will be conducted at SingHealth Polyclinics.

03

Conditions studied

  • Asthma
  • Asthma Attack
  • Asthma in Children
  • Asthma Acute
  • Asthma Chronic

Browse trials for

04

Who can participate

Ages eligible
7 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of asthma
  • Pediatric patients (age 7 to 17), adult patients (age 18 and above
  • Have an asthma exacerbation on the day of visit
  • Be willing to use the AeviceMD device
  • Has a smart phone to download the application that is paired with Aevice
  • Has wireless fidelity (WIFI) connection to use with Aevice
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • No capacity for consent
  • Concurrent (COPD)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
173 participants (actual)

Study arms

  • Active comparator
    Control group

    The control group will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.

    Behavioral: Standard care

  • Experimental
    Intervention group

    The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management

    Device: AeviceMD device · Behavioral: Standard care

Interventions

  • DeviceAeviceMD device

    The intervention group will receive the AeviceMD device on top of standard care provided by the Polyclinic. They will use the AeviceMD device for 12 weeks. They are expected to use the device for at least 5 hours at night when they are asleep. However, they can also use the device at any time of the time, based on their own preference. The AeviceMD device will provide patients with objective information of their breathing (respiratory rate) and lung sounds. This objective information can be used for participants to self-manage their asthma following the asthma action plan. During the clinical follow-up, participants can show the clinician their lung parameters, to improve clinical management

  • BehavioralStandard care

    All participants will receive the standard care provided by the Polyclinic. This can include a telephone follow-up by a nurse within 5 days, and follow-ups with a doctor after one week. All patients with asthma should also have an asthma action plan which provides them instructions on how to manage their asthma and the medications required when they experience symptoms. These symptoms include wheezing, chest tightness, difficulty breathing, coughing, night-waking, and symptom interfering with day-to-day activities.

06

What researchers measure

Primary outcomes

  1. Rescue therapy

    number of times

    Time frame: up to 12 weeks

  2. Dose of oral Prednisolone use

    Total dose in mg

    Time frame: up to 12 weeks

  3. Visit to hospital emergency department

    number of times

    Time frame: up to 12 weeks

  4. Hospitalisation

    total number of days

    Time frame: up to 12 weeks

  5. Euro Quality of Life 5 dimensions (EQ5D)

    The Euro Quality of Life 5 dimension evaluates five items related to health: 1. mobility, 2. self-care, 3. usual activities, 4. pain/discomfort, and 5. anxiety/depression. A 5-point Likert scale is used for adults, ranging from no problems, slight problems, moderate problems, severe problems, and extreme problems. Scores from the five items can be used to derive a single utility score.

    Time frame: up to 12 weeks (baseline, week 4, week, 12)

  6. Asthma quality of life questionnaire (AQLQ)

    The asthma quality of life questionnaire (AQLQ) will be used for participants above age 18. It consists of 32 items divided into four sections: symptoms (11 items), activity limitations (12 items), emotional function (5 items), and environmental stimuli (4 items). The intraclass correlation coefficient is 0.95. Each question is rated on a 7-point Likert scale. The Cronbach alpha is 0.9.

    Time frame: up to 12 weeks (baseline, week 4, week, 12)

  7. Pediatric asthma quality of life questionnaire (PAQLQ)

    The Paediatric asthma quality of life questionnaire (PAQLQ) will be used for Paediatrics age 7 to 17. It consists of 23 items in 3 domains: activity limitation (5 items), symptoms (10 items) and emotional function (8 items). The questionnaire has been validated in Singapore, with intraclass correlation coefficient of 0.71

    Time frame: up to 12 weeks (baseline, week 4, week, 12)

Secondary outcomes

  1. Self-efficacy

    Self-efficacy will be measured using a self-developed questionnaire consisting of 6 questions. Each question will be rated on a 5-point Likert scale (strongly agree to strongly disagree). This is to evaluate if Aevice was useful for self-management of asthma

    Time frame: up to 12 weeks, intervention group

  2. Usability

    The usability of device will be measured using the system usability scale (SUS). The scale consists of 10 items, rated on a 5-point Likert scale (score 1 to 5), with scores ranging from 10 to 50. Higher scores represent higher usability.

    Time frame: up to 12 weeks, intervention group

  3. Heart rate

    Heart rate per minute, data obtained from the device. to record the average heart rate, and frequency of being out of range.

    Time frame: Throughout 12 weeks of study, intervention group

  4. Respiratory rate

    respiratory rate per minute, data obtained from the device. To track average respiratory rate, and frequency of being out of range

    Time frame: Throughout 12 weeks of study, intervention group

  5. Wheeze detection trend

    wheeze detection, data obtained from the device. The number of wheeze per day, and number of days with wheeze will be recorded

    Time frame: Throughout 12 weeks of study, intervention group

  6. Medication log

    participant self entry of medication into the application, which will be obtained from the application. This will track patient frequency of taking inhaler

    Time frame: Throughout 12 weeks of study, intervention group

  7. Duration of device usage

    number of hours use per day on average, and number of days used

    Time frame: Throughout 12 weeks of study, intervention group

  8. Payment

    Amount the patient is willing to pay for the use of the device, in Singapore dollars

    Time frame: 12 week, intervention group

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Jan 2026, 20 months.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's 20 months is below that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Sep 2025 → Jan 2026 and completion Dec 2025 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 22, 2024
StartActual
May 1, 2024
Primary completionActual
Jan 30, 2026was Sep 2025
CompletionActual
Mar 30, 2026was Dec 2025
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Sites
1 site added, 1 site removed
Show site
  • SingHealth Polyclinics · Singapore, Singapore
Show 1 removed
  • SingHealth Polyclinics · Singapore, Singapore
Nov 18, 2026
Primary completion
Sep 30, 2025→Jan 30, 2026 (actual)
Nov 18, 2026
Study completion
Dec 30, 2025→Mar 30, 2026 (actual)
Nov 18, 2026
Enrollment
180 (estimated)→173 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • SingHealth Polyclinics · Singapore, Singapore
    Show 1 removed
    • SingHealth Polyclinics · Singapore, Singapore
    Primary completion Sep 30, 2025→Jan 30, 2026 (now actual)
    Study completion Dec 30, 2025→Mar 30, 2026 (now actual)
    Enrollment 180 (estimated)→173 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06377345
Lead sponsor
SingHealth Polyclinics
Responsible party
Mabel Leow Qi He (Principle Investigator, SingHealth Polyclinics) — Principal investigator
First posted
Apr 22, 2024
Start date
May 1, 2024
Primary completion
Jan 30, 2026
Completion
Mar 30, 2026
Last update
Nov 18, 2026

Study contacts

Mabel QH Leow, PhD
principal investigator · SingHealth Polyclinics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion